This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

79/100

✓ Peer-reviewed alzhub usefulness score 79 out of 100. Biomarkers

Topic: Amyloid, tau and blood-test diagnosis

Plain-language summary

Results Among 171 Aβ-positive CU participants included in the main analyses, 119 (mean [SD] age, 73.0 [5.4] years; 60.5% female) were from the BioFINDER-1 study, and 52 (mean [SD] age, 64.4 [4.6] years; 65.4% female) were from the WRAP study. These findings suggest that plasma P-tau217 may be used as a complement to CSF or PET for participant selection in clinical trials of novel disease-modifying treatments.

What this study adds

Evidence grade: Moderate

This is a follow-up (cohort) study of 564 participants. This study followed people from two research cohorts, BioFINDER-1 and WRAP, who had amyloid in the brain but were described as cognitively unimpaired: 171 people in the main analyses. Reported effect size: 60.5%; 65.4%.

Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Mattsson-Carlgren, N., Salvadó, G., Ashton, N. J., Tideman, P., Stomrud, E., Zetterberg, H., et al. (2023). Prediction of Longitudinal Cognitive Decline in Preclinical Alzheimer Disease Using Plasma Biomarkers. JAMA neurology. https://doi.org/10.1001/jamaneurol.2022.5272

Vancouver

Mattsson-Carlgren N, Salvadó G, Ashton NJ, Tideman P, Stomrud E, Zetterberg H, et al. Prediction of Longitudinal Cognitive Decline in Preclinical Alzheimer Disease Using Plasma Biomarkers. JAMA neurology. 2023. doi:10.1001/jamaneurol.2022.5272. PMID: 36745413.

BibTeX

@article{mattssoncarlgren2023-36745413,
  author  = {Mattsson-Carlgren, N. and Salvadó, G. and Ashton, N. J. and Tideman, P. and Stomrud, E. and Zetterberg, H. and Ossenkoppele, R. and Betthauser, T. J. and others},
  title   = {{Prediction of Longitudinal Cognitive Decline in Preclinical Alzheimer Disease Using Plasma Biomarkers}},
  journal = {JAMA neurology},
  year    = {2023},
  doi     = {10.1001/jamaneurol.2022.5272},
  pmid    = {36745413},
  url     = {https://doi.org/10.1001/jamaneurol.2022.5272}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.

How to read this study

Design: this is a follow-up (cohort) study. People are observed over time and not assigned to anything, so an association can reflect other differences between groups. Look at how long follow-up lasted, how many dropped out, and whether the authors adjusted for age, education and other health conditions.
Size: the record lists 564 participants. Ask whether that is enough for the question, and who they were.
Effect: the record reports “60.5%; 65.4%”. A statistically significant result can still be small in daily life.

What the evidence grade means here

This page is graded moderate. alzhub.org assigns the grade automatically from keywords in the abstract, not from reading the paper. Moderate means the abstract mentions a cohort, case-control or longitudinal design. It can add at most 5 of the 100 points in the study score, and it is a label about design, not a verdict on whether the findings are true.

New to reading papers? Six questions to ask of any Alzheimer’s study · how we score.

Key findings

Results Among 171 Aβ-positive CU participants included in the main analyses, 119 (mean [SD] age, 73.0 [5.4] years; 60.5% female) were from the BioFINDER-1 study, and 52 (mean [SD] age, 64.4 [4.6] years; 65.4% female) were from the WRAP study.
These findings suggest that plasma P-tau217 may be used as a complement to CSF or PET for participant selection in clinical trials of novel disease-modifying treatments.

Why it matters

This study followed people from two research cohorts, BioFINDER-1 and WRAP, who had amyloid in the brain but were described as cognitively unimpaired: 171 people in the main analyses. It asked whether blood markers predict later memory and thinking decline at this "preclinical" stage. The authors conclude that the blood test plasma P-tau217 "may be used as a complement to CSF or PET" when choosing participants for trials of new disease-modifying treatments. That is a finding about trial recruitment, not about a treatment, and our record does not include the figures showing how well the test predicted decline.

New to this subject? Start with our plain-English guide: Blood tests & biomarkers →

Study details

Study designcohort study
Participants564
Effect size60.5%; 65.4%
Evidence strengthModerate

How this study scored 79/100

Published in a leading specialty journal, and it is a cohort study following people over time. Scored zero for randomized / blinded because the record does not state it.

Component	Points	Why
Journal tier	9 / 10	Tier 2 — leading specialty journal (JAMA neurology)
Journal's citation record	2 / 4	JAMA Neurology: journal h-index 235 (OpenAlex, 2026-10-29)
Study design	7 / 12	A cohort study following people over time
Strength of evidence	3 / 5	Rated “moderate” in our summary
Peer-review validation	10 / 10	Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent	3 / 5	2023 — within 6 year(s) of the newest study here
Sample size	2 / 4	564 participants
Effect reported	2 / 3	Effect reported as a number, without an interval or test
Studied in people	3 / 3	Studied in people (participant count stated)
Randomized / blinded	0 / 2	No randomization or blinding stated — scores zero (not stated in the record — scored 0)
Times cited	6 / 7	Cited 308 times (OpenAlex, 2026-10-10)
Citations per year	5 / 5	61.6 citations a year over 5 year(s) since 2023
Impact for its field and year	6 / 6	Cited 55.5× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here	4 / 6	Cited by 43 other studies in this library
Still being cited	4 / 4	Cited 280 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record	4 / 4	Last-listed author Oskar Hansson: h-index 148 (OpenAlex, whole career)
Institution's track record	2 / 3	University College London: institution h-index 2,029 (OpenAlex)
Multicenter collaboration	3 / 3	OpenAlex lists 14 institution(s) in 5 countries
Indexed in PubMed	2 / 2	Indexed in PubMed (PMID 36745413)
Free to read	2 / 2	Free to read
Total	79 / 100	—

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — PubMed Central lists this copy as free to read: the link above (checked 10 Oct 2026).

Studies in the library that share something with this one. The line above each title says what.

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 22.

Later studies that cite this one

43 studies in the alzhub library list this one in their references. Showing the 8 highest-scoring.

Related studies in Biomarkers from nearby years

Also tagged “cerebrospinal”

820 studies in the library carry the topic tag “cerebrospinal”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 820 tagged studies.

Studies sharing this one's topic tags

Similar studies

More on Biomarkers

See all studies in Biomarkers →